EU Panel Recommends Luxturna for Inherited Retinal Dystrophy

Share this post

The EMA’s CHMP has recommended marketing authorization for voretigene neparvovec for inherited retinal dystrophy caused by RPE65 gene mutations in adults and children.
International Approvals

This post was syndicated from Medscape Medical News Headlines. Click here to read the full text on the original website.

Share this post

Be the first to comment

Leave a Reply